Journal of the American Heart AssociationHumansMyocarditisMaleFemaleImmune Checkpoint Inhibitors
Short- and Long-Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors.
Ankit Agrawal, Akiva Rosenzveig, Ahmad Safdar, Danial Nasif, Umesh Bhagat, Jibran Ikram, Muhammad Ehsan, Muhammad Majid, Ashwin Kumar, Aro Daniela Arockiam, Beni R Verma, Julia Wajsberg, Allan L Klein
Published: 202610.1161/JAHA.125.041163
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry a risk of immune-related adverse events, reported in 15% to 90% of the patients. ICI-associated pericardial and myocardial disease has been increasingly re…
Preview only. Read the full abstract at the source